Boston University School of Public Health, Department of Health Law, Policy, and Management, Boston, MA.
Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA.
Addict Behav. 2024 Jan;148:107873. doi: 10.1016/j.addbeh.2023.107873. Epub 2023 Sep 29.
Non-fatal overdoses are underreported and there is no accepted and feasible self-report research measure of non-fatal opioid overdose. Timeline follow-back (TLFB) calendar-based questionnaires assess self-reported risk behaviors. We assessed feasibility and acceptability of a new TLFB research measure for opioid use, non-fatal opioid overdose, and substance use disorder treatment among opioid overdose survivors.
For the Repeated-dose Behavioral Intervention to Reduce Opioid Overdose Trial (REBOOT) study among opioid overdose survivors, we developed a TLFB questionnaire to assess daily non-prescribed opioid use, opioid overdose, facility stays, medications/behavioral treatment for opioid use disorder, and COVID-19 history during the previous 120 days. Staff assessors administered TLFB at four-monthly visits over the 16-month study participation period. To measure feasibility, we estimated TLFB completion time using an electronic timestamp tool. To measure acceptability, we administered a satisfaction survey to 103 participants who completed REBOOT.
Among 525 TLFB assessments conducted in 174 participants from January 2021-January 2023, opioid use was reported in 510 assessments, medication for opioid use disorder (MOUD) in 331 assessments, and ≥ 1 overdose in 107 assessments. Median TLFB completion time was 11 (IQR: 6-17) minutes for sections administered to all participants; detailed overdose questions administered to those reporting overdose took an additional 3 (IQR: 2-6) minutes. Report of ≥ 1 overdose and MOUD use were significantly associated with increased TLFB completion time. 88 % of participants reported that TLFB was very/somewhat acceptable.
Among opioid overdose survivors, REBOOT TLFB was a feasible and acceptable research measure, with similar completion time as other TLFB assessments of substance use.
非致命性过量用药的报告不足，且目前尚无被广泛接受和切实可行的针对非致命性阿片类药物过量用药的自我报告研究方法。时间线回溯（TLFB）基于日历的问卷可评估自我报告的风险行为。我们评估了一种新的 TLFB 研究方法在阿片类药物过量幸存者中评估阿片类药物使用、非致命性阿片类药物过量和物质使用障碍治疗的可行性和可接受性。
在针对阿片类药物过量幸存者的重复剂量行为干预以减少阿片类药物过量试验（REBOOT）研究中，我们开发了一种 TLFB 问卷，以评估过去 120 天内每日非处方阿片类药物使用、阿片类药物过量、住院、阿片类药物使用障碍的药物/行为治疗和 COVID-19 病史。工作人员评估员在研究参与的 16 个月期间每四个月进行一次 TLFB 评估。为了衡量可行性，我们使用电子时间戳工具估计 TLFB 完成时间。为了衡量可接受性，我们向完成 REBOOT 的 103 名参与者进行了满意度调查。
在 2021 年 1 月至 2023 年 1 月期间，对 174 名参与者中的 525 次 TLFB 评估中，有 510 次评估报告了阿片类药物使用，331 次评估报告了阿片类药物使用障碍药物（MOUD），107 次评估报告了≥1 次过量用药。所有参与者接受的 TLFB 部分的中位数完成时间为 11（IQR：6-17）分钟；向报告过量用药的参与者提供的详细过量用药问题另外需要 3（IQR：2-6）分钟。报告≥1 次过量用药和 MOUD 使用与 TLFB 完成时间的增加显著相关。88%的参与者报告 TLFB 非常/有些可接受。
在阿片类药物过量幸存者中，REBOOT TLFB 是一种可行且可接受的研究方法，其完成时间与其他物质使用的 TLFB 评估相似。
